Clinical Trial Update: Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial of peripheral blood lymphocyte therapy using EBV-specific cytotoxic T cells to prevent EBV-related lymphoproliferative disorders after transplanta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Peripheral Blood Lymphocyte Therapy (EBV-specific cytotoxic T cells) (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Northwestern University | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED